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anes for ovarian and breast cancer, proton pump inhibi-
tors in the treatment of dyspepsia, glycoprotein IIb/IIIa
inhibitors, methylphenidate for hyperactivity in child-
hood, zanamivir, and rosiglitazone for type II Diabetes
Mellitus. The analysis of the evidence shows that the ef-
fectiveness of these drugs has been demonstrated in the
last 12 years. However, cost-effectiveness evidence has
been published for 70% of the drugs with an average de-
lay of 3 years (range 0–10). The cost-effectiveness of
those, introduced after 1995 (80% of all included drugs/
drug groups), has been demonstrated using models only,
if at all. CONCLUSIONS: Cost-effectiveness evidence is
produced with a lag behind the effectiveness evidence. As
a result, decision-makers are in a position of awaiting
sound evidence while issuing guidance based on current
inconclusive research results. The cost to society is dis-
cussed, and establishing the cost-effectiveness of new
drugs alongside RCTs at an earlier stage of their develop-
ment is suggested.
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BACKGROUND: As more European governments re-
quire economic data to support reimbursement applica-
tions the potential burden of multiple economic evalua-
tions is being seen as a problem by industry. Placing
responsibility for cost-effectiveness assessment at the Eu-
ropean level using standardised methods has been pro-
posed as a solution. OBJECTIVE: To review the feasibil-
ity of a European level cost-effectiveness test for new
drugs, from conceptual, practical and political view-
points. METHODS: The issues are examined first from
the theoretical perspective—does a European level eco-
nomic evaluation have any inherent logic. Secondly, the
practical issues of how such an evaluation might be con-
ducted are examined. Could it be based on a phase III
clinical trial? The political issues relate to who would reg-
ulate the production of such cost-effectiveness data; who
would use the data to assist in what decision(s)? Different
regulatory models are assessed using the analogy of drug
licensing. DISCUSSION: The position generally taken by
economists is that a generalised cost-effectiveness result is
neither possible nor useful. Differences in the price struc-
tures, treatment patterns and provider incentives between
systems make generalisations of cost-effectiveness of
questionable relevance. How fast will European integra-
tion produce a single health market? Moves towards a
single European price for each drug are relevant as in the
willingness of European states to allow the EU to play a
bigger role in health care financing and organisation.
Will countries accept each others’ assessments or will an
EU agency like EMEA be required? CONCLUSIONS:
Long-term political and economic changes may well cre-
ate a true European market in which cost-effectiveness at
the European level will have meaning and relevance.
Meanwhile, individual country health care systems seem
more concerned with short-term budget impact when
making new drugs available. The pharmaceutical indus-
try should not anticipate a reduction in the overall de-
mand for locally targeted economic information.
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BACKGROUND: The three-tier copayment plan is de-
signed to reduce the cost of pharmacy benefits to the in-
surer or payer while maintaining patient choice. Because
the patient pays a larger portion of the cost of middle-
and high-tier drugs, some have argued that this plan de-
sign may adversely impact patient drug utilization for
chronic medications. OBJECTIVE: To determine whether
a three-tier copayment structure adversely affects patient
drug utilization for middle- and upper-tier drugs for dia-
betes and depression. METHODS: We conducted a lon-
gitudinal, retrospective claims database study using claims
data from a national pharmaceutical benefits management
company. Claims for two chronic conditions, depression
and oral diabetes, were examined for patients on three-tier
copayment plans and for patients on an open formulary
plan with the same copayment for every drug. Average
rates of patient adherence, number of prescriptions filled,
and days of therapy were calculated. RESULTS: There
were statistically significant differences in rates of patient
adherence, number of prescriptions filled, days of therapy,
amount of copay, and payer costs among patients using
drugs in the lower, middle, or upper tier of the three-tier
structure. In addition, average patient adherence, number
of prescriptions filled, and days of therapy did differ signif-
icantly for patients on an open formulary compared to pa-
tients on a three-tier copayment structure. These differ-
ences were largely a function of sample size, and may be of
little practical utility.CONCLUSIONS: The larger patient
copayment for medications in the middle and upper tiers
of a three-tier copayment structure have only a minimal
impact on drug utilization in the antidepressant and oral
diabetes drug categories. Further research is needed to de-
termine whether these findings would be replicated when
applied to other therapeutic classes.
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